HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Proteomic analyses reveal high expression of decorin and endoplasmin (HSP90B1) are associated with breast cancer metastasis and decreased survival.

AbstractBACKGROUND:
Breast cancer is the most common malignancy among women worldwide in terms of incidence and mortality. About 10% of North American women will be diagnosed with breast cancer during their lifetime and 20% of those will die of the disease. Breast cancer is a heterogeneous disease and biomarkers able to correctly classify patients into prognostic groups are needed to better tailor treatment options and improve outcomes. One powerful method used for biomarker discovery is sample screening with mass spectrometry, as it allows direct comparison of protein expression between normal and pathological states. The purpose of this study was to use a systematic and objective method to identify biomarkers with possible prognostic value in breast cancer patients, particularly in identifying cases most likely to have lymph node metastasis and to validate their prognostic ability using breast cancer tissue microarrays.
METHODS AND FINDINGS:
Differential proteomic analyses were employed to identify candidate biomarkers in primary breast cancer patients. These analyses identified decorin (DCN) and endoplasmin (HSP90B1) which play important roles regulating the tumour microenvironment and in pathways related to tumorigenesis. This study indicates that high expression of Decorin is associated with lymph node metastasis (p<0.001), higher number of positive lymph nodes (p<0.0001) and worse overall survival (pā€Š=ā€Š0.01). High expression of HSP90B1 is associated with distant metastasis (p<0.0001) and decreased overall survival (p<0.0001) these patients also appear to benefit significantly from hormonal treatment.
CONCLUSIONS:
Using quantitative proteomic profiling of primary breast cancers, two new promising prognostic and predictive markers were found to identify patients with worse survival. In addition HSP90B1 appears to identify a group of patients with distant metastasis with otherwise good prognostic features.
AuthorsThomas R Cawthorn, Juan C Moreno, Moyez Dharsee, Danh Tran-Thanh, Suzanne Ackloo, Pei Hong Zhu, Girish Sardana, Jian Chen, Peter Kupchak, Lindsay M Jacks, Naomi A Miller, Bruce J Youngson, Vladimir Iakovlev, Cynthia J Guidos, Katherine A Vallis, Kenneth R Evans, David McCready, Wey L Leong, Susan J Done
JournalPloS one (PLoS One) Vol. 7 Issue 2 Pg. e30992 ( 2012) ISSN: 1932-6203 [Electronic] United States
PMID22363530 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Neoplasm
  • Biomarkers, Tumor
  • Decorin
  • Membrane Glycoproteins
  • Neoplasm Proteins
  • Peptides
  • endoplasmin
Topics
  • Amino Acid Sequence
  • Antibodies, Neoplasm (immunology)
  • Biomarkers, Tumor (metabolism)
  • Breast Neoplasms (immunology, metabolism, pathology)
  • Decorin (metabolism)
  • Disease-Free Survival
  • Female
  • Humans
  • Immunohistochemistry
  • Lymphatic Metastasis (pathology)
  • Mass Spectrometry
  • Membrane Glycoproteins (metabolism)
  • Molecular Sequence Data
  • Multivariate Analysis
  • Neoplasm Proteins (chemistry, metabolism)
  • Peptides (chemistry, metabolism)
  • Proteomics (methods)
  • Reproducibility of Results

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: